Caxton Associates LP Invests $314,000 in BioLife Solutions, Inc. (NASDAQ:BLFS)

Caxton Associates LP acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 12,112 shares of the medical equipment provider's stock, valued at approximately $314,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Invesco Ltd. lifted its stake in shares of BioLife Solutions by 1.1% in the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider's stock valued at $84,097,000 after purchasing an additional 36,176 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of BioLife Solutions by 4.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider's stock valued at $23,028,000 after purchasing an additional 40,416 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in shares of BioLife Solutions by 40.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 821,764 shares of the medical equipment provider's stock valued at $21,333,000 after purchasing an additional 236,267 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $20,664,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $19,805,000. Institutional investors and hedge funds own 93.24% of the company's stock.

Insider Buying and Selling

In related news, insider Sarah Aebersold sold 1,091 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $27,275.00. Following the sale, the insider now directly owns 58,816 shares of the company's stock, valued at approximately $1,470,400. The trade was a 1.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CMO Todd Berard sold 8,902 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $201,719.32. Following the completion of the sale, the chief marketing officer now directly owns 135,956 shares in the company, valued at $3,080,762.96. This represents a 6.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,127 shares of company stock valued at $1,676,533. 2.20% of the stock is owned by company insiders.

Analyst Ratings Changes

BLFS has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Tuesday. StockNews.com downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $31.17.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS traded down $0.73 during mid-day trading on Tuesday, hitting $23.16. 97,255 shares of the stock were exchanged, compared to its average volume of 380,408. The company has a market cap of $1.10 billion, a P/E ratio of -21.85 and a beta of 2.01. The stock's fifty day simple moving average is $23.79 and its two-hundred day simple moving average is $25.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a twelve month low of $18.70 and a twelve month high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $23.94 million for the quarter, compared to analyst estimates of $22.22 million. As a group, analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.